Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Skylight Health (SLHG) expands its Colorado primary care network to act as a clinical research site partner for ClinEdge
  • The expanded partnership with ClinEdge will bring industry-sponsored trials to Skylight Health’s clinics in Colorado
  • Skylight announces the award of its first clinical trial in Colorado as part of its partnership with ClinEdge adding to its previously announced trial in Massachusetts on June 2, 2021
  • The research project has already begun for the study and Skylight will be responsible for consenting, enrolling, and observing patients during the four-week research trial
  • While this study is relatively short, Skylight Health will expect to have the study completed by the end of Q3 2021
  • Skylight Health Group Inc (SLHG) is up 0.73 per cent trading at C$4.14 at 11:52 am ET

Skylight Health Group Inc (SLHG) is expanding its partnership with ClinEdge, one of North America’s leading clinical research groups.

Skylight previously announced a partnership with ClinEdge to bring industry-sponsored clinical trials to one of its primary care clinics in Massachusetts.

The success of this partnership has led to an expansion of the initial contract, and Skylight has now been awarded its first Colorado-based research project through ClinEdge.

“This momentum is exciting for the research program within Skylight and Colorado remains a key market for the company,” said Prad Sekar, CEO of Skylight Health.

“As a national value-based healthcare provider, leveraging our existing infrastructure for patient-centric research projects works to further enhance the value that we are able to bring to our patients, and the US healthcare industry at large,” added Sekar.

The research project has begun recruiting for the study and Skylight will be responsible for consenting, enrolling, and observing patients during the four-week research trial. Both Skylight Health and patients taking part in the study will be compensated.

While this study is relatively short, Skylight Health will expect to have the study completed by the end of Q3 2021. Details of the trial are held in confidence to comply with study protocols and necessary regulatory requirements.  

Skylight Health expects to continue to grow its research efforts into additional markets and ClinEdge has proven to be an excellent partner for this growth effort.

The company also announced that Skylight Health’s disinterested common shareholders approved the adoption of an omnibus long-term incentive plan at its annual and Special Meeting of Shareholders held on June 29, 2021.

The Omnibus Plan permits the equivalent of up to 10 per cent of Skylight Health’s issued and outstanding common shares to be issued together with 3,600,000 common shares of Skylight Health as performance share units, restricted share units, and deferred share units.

Skylight also issued 87,779 shares pursuant to the River City Medical Associates Acquisition announced in February.

Skylight Health Group is a healthcare services and technology company that operates a primary care health network providing primary care, sub-specialty, allied health, and laboratory/diagnostic testing.

Skylight Health Group Inc (SLHG) is up 0.73 per cent trading at C$4.14 at 11:52 am ET.

More From The Market Herald

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.
Nanalysis (TSXV:NSCI) - Founder & CEO, Sean Krakiwsky.

" Nanalysis (TSXV:NSCI) signs $160M security contract

Nanalysis Scientific (NSCI) has signed a six-year $160 million contract with Canadian Air Transportation Security Authority (CATSA).
Lifeist Wellness Inc - CEO, Meni Morim

" Lifeist Wellness (TSXV:LFST) announces sale of Swedish subsidiary Findify

Lifeist Wellness (LFST) announced the sale of Findify AB, the company’s Swedish subsidiary that operates an AI-powered product search and discovery platform.

" DIAGNOS (TSXV:ADK) testing autonomous AI solutions for diabetic retinopathy screening

Diagnos (ADK) is launching the testing phase for autonomous artificial intelligence solutions dedicated to diabetic retinopathy screening.